Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR4 in Mild-to-Moderate Asthma
NCT07272135Phase 1Completed
- Sponsor
- Trio Medicines Ltd
- Start
- Feb 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TR4 in asthma, sponsored by Trio Medicines Ltd. Primary endpoints: Mannitol Provocative Dose causing 15% fall in FEV1, Forced Expiratory Volume in 1 second at Day 21 and 6 more. Started Feb 2018; status: completed.
02
Drugs
TR4
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07272135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272135.